Stock Ratings / Health Care / CRVO / dividends

SHPH (41) MIRA (36) IMMP (47) CELU (26) ⌘ Pro Terminal →

CervoMed Inc. (CRVO) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Does CRVO pay a dividend and is it safe?

CervoMed Inc. (CRVO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$1.60 -8.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.57

CervoMed Inc. (CRVO) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $24.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRVO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, CervoMed Inc. (NASDAQ: CRVO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.60 (-8.57% 1D, market cap $24.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRVO ranks #869 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRVO compare to SHPH and MIRA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVO carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SHPH (Shuttle Pharmaceuticals Holdings Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $24.5M) and MIRA (MIRA Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $23.0M). Among the 5-stock peer group, CRVO leads on earnings multiple (N/A) while CRVO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRVO?

▼

Per CRVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001053691), CervoMed Inc. generated $4.0M in revenue (-58.9% YoY), -$27.0M in net income, and -$23.4M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.57 (-1.73%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRVO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY CRVO SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.27+0.9% Next Q

Q2 (-2Q)

Grade E$2.29-3.1% Next Q

Q3 (-1Q)

Grade E$2.22-27.9% Next Q

Current

Grade E$1.60-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRVO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRVO currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.51) and Max Pain ($1.68) forces dealer call-delta covering toward $10.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRVO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRVO)

✓Walkthrough of CRVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.76%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.75H $1.75L $1.60C $1.60VOL 585.4K

RES: $3.56SUP: $1.56SMA50: $2.51SMA200: $3.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRVO Butterfly Map → + Track CRVO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -58.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRVO)

Health Care Rank #869 of 1016 ⚔️ SHPH vs CRVO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRVO vs. SHPH, MIRA, IMMP, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CervoMed Inc. (CRVO) ranks #869 by composite RQD confidence (28/100, grade E) and #821 by equity capitalization ($24.2M). Within this direct 5-issuer industry benchmark cohort, CRVO leads on earnings valuation at N/A trailing P/E, while CRVO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CRVO at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRVO ACTIVE CervoMed Inc.	E	28/100	—	—	-35.0%	-8.57%	$24.2M	Benchmark Subject
SHPH Shuttle Pharmaceuticals Holdings Inc.	D-	41/100	—	—	-35.0%	-1.53%	$24.5M	/shph-vs-crvo →
MIRA MIRA Pharmaceuticals Inc.	D-	36/100	—	—	-35.0%	-4.04%	$23.0M	/mira-vs-crvo →
IMMP Immutep Limited	D	47/100	—	—	—	-8.11%	$22.6M	/immp-vs-crvo →
CELU Celularity Inc. (Class A)	E	26/100	—	24.4%	-35.0%	-5.79%	$26.0M	/celu-vs-crvo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001053691

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CervoMed Inc. (CRVO) reported GAAP revenue of $4.0M (-58.9% vs. FY2024 revenue of $9.7M , and -43.9% cumulative change since FY2023) , GAAP net income of -$27.0M, operating cash flow of -$23.4M, and free cash flow of -$23.4M (-41.9% YoY). On the balance sheet, CRVO closed FY2025 with $22.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.0M	-$27.0M	-$23.4M	-$23.4M	$22.9M	—
FY2024 (FY)	2024-12-31	$9.7M	-$16.3M	-$16.5M	-$16.5M	$43.1M	—
FY2023 (FY)	2023-12-31	$7.1M	-$2.2M	-$7.4M	-$7.4M	—	—

3. CRVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRVO compare to SHPH and MIRA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRVO?

Where is CRVO trading relative to its 50-day, 200-day, and 52-week technical levels?

CRVO last traded at $1.60 (-8.57% on volume of 585,352 shares), positioning the stock -36.25% below its 50-day simple moving average ($2.51) and -53.62% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.60 to $10.00, CRVO sits at the 0.0% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.40 to $1.80).

CRVO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CRVO pay a dividend and is it safe?

CervoMed Inc. (CRVO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CRVO RQD Cockpit CRVO 12M Forecast CRVO Earnings & Move CRVO Dividends & DRIP CRVO Insiders & 13F CRVO Whale Options CRVO Profit Sankey CRVO News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CRVO — CervoMed Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:11Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CRVO scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 7 / 20. The pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to shareholders.
Whale 13F Flow: 3 / 20. This pillar covers institutional accumulation and options positioning. The low score signals weak institutional support in the source data.
Insider Conviction: 3 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. The low score indicates the insider-activity signal is weak, though the news wire references option grants to executives (see Recent Catalysts).
Macro Regime Fit: 7 / 20. Beta is 1.0 and the pillar reflects sector sensitivity. The score is modest and does not, on its own, indicate a macro-driven advantage or disadvantage.
Forensic Balance Sheet: 8 / 20. The pillar reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The Piotroski score is weak, and the balance sheet offers limited forensic comfort.

Taken together, the rating frames CRVO as a high-risk, forensically weak name. The stock's -20.81% move and its position near the bottom of its 52-week range ($1.6 - $10) are consistent with the rating's negative read. Upside cases would depend on factors outside the financial pillars, such as pipeline catalysts, which the source data does not quantify.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$4.0M	$-28.3M	$-27.0M	N/A	$-23.4M	$8.2M	N/A
FY 2024	$9.7M	$-18.2M	$-16.3M	N/A	$-16.5M	$9.0M	N/A
FY 2023	$7.1M	$-7.8M	$-2.2M	N/A	$-7.4M	N/A	N/A

Per the SEC financials, revenue declined from $9.7M in FY 2024 to $4.0M in FY 2025, while operating losses widened from $-18.2M to $-28.3M. Net margin and operating margin are each -60% per the market data, and gross margin is 0%. ROIC is -35% and FCF yield is 0%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Cash declined from $9.0M to $8.2M across FY 2024 to FY 2025. Debt is listed as N/A in the reported periods.

Recent Catalysts & News Wire Analysis

Analyst reiteration (YELLOW, MARKET WIRE): H.C. Wainwright reiterated a Buy on CRVO on a new formulation, per the Investing.com headline.
Milestone framing (YELLOW, MARKET WIRE): A kalkine.ca headline attributes a 16% slide to pending Neflamapimod milestones.
Nerve-damage marker (RED, RISK WATCH): A Stock Titan headline reports that CervoMed saw a nerve-damage marker fall over 12 weeks, in the context of a rare dementia with no approved drug.
Executive option grants (RED, RISK WATCH): Stock Titan reports options at a $2.24 exercise price granted to executive Mark De Rosch, and a separate grant of 19,100 options at $2.24 to Matthew Winton.
Q2 2026 earnings (GREEN, CATALYST): A headline describes a narrower-than-expected loss that beat consensus, with shares slipping. The source attribution for this item is a non-news domain.

The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Open Questions

What are the specific pipeline assets and clinical milestones behind the Neflamapimod references, and what is their timing?
What drove the revenue decline from $9.7M in FY 2024 to $4.0M in FY 2025?
What are the P/E, EV/EBITDA, and EPS figures given the reported net losses?
What is the debt position, given that debt is listed as N/A across reported periods?
What is the source and verification status of the Q2 2026 earnings headline, given its non-news attribution?

CRVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CervoMed Inc. (CRVO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRVO Debate Forum (3) ↓

🟡 MARKET WIRE Investing.com • 19h ago

H.C. Wainwright reiterates Buy on CervoMed stock on new formulation

Investing.com report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 22h ago

Pending Neflamapimod Milestones Frame 16% Slide in Penny Stock CervoMed (NASDAQ:CRVO)

kalkine.ca report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

A rare dementia can take away speech; no drug is approved for it. CervoMed saw a nerve-damage marker fall over 12 weeks.

Stock Titan report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

Options at $2.24 a share go to CervoMed (CRVO) executive Mark De Rosch.

Stock Titan report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

With a $2.24 exercise price, CervoMed (CRVO) awards Matthew Winton 19,100 stock options.

Stock Titan report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

CRVO Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, Shares Slip - Profit Warning Alert

https://www.dars.gov.et/ report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Options covering 19,100 shares vest over 36 months for CervoMed (CRVO)'s clinical development EVP.

Stock Titan report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

CRVO Q2 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Keeps a Tight Lid on Spending - Margin Compression Risk

https://www.dars.gov.et/ report covering CervoMed Inc. (CRVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRVO Bull vs. Bear Conversation Board — What's Your Call at $1.60?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRVO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.54 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CRVO (E • RQD 28/100) a Buy at $1.75?

Welcome to the CRVO (CervoMed Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.37 (-21.7%)

Spot @ $1.75

Pump the brakes on CRVO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CRVO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless CervoMed Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.10 (+20.0%)

Spot @ $1.75

CRVO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CRVO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.75 (52-wk range $1.60 - $10.00), any beat on forward guidance forces shorts and underweight funds to chase.